

Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. According to data from the Phase III TROPION-Lung01 trial, datopotamab deruxtecan appears to be more efficacious in patients with which type of previously treated advanced non-small cell lung cancer (NSCLC)?
 - a. Squamous
 - b. Nonsquamous**
 - c. Neither a nor b — patients with either histology benefitted equally
2. Updated analysis from the Phase III CheckMate 9LA study demonstrated a benefit in median overall survival (OS) with nivolumab/ipilimumab and 2 cycles of chemotherapy compared to chemotherapy alone for which of the following populations of patients with metastatic NSCLC?
 - a. Patients with a PD-L1 level of 1% or higher
 - b. Patients with a PD-L1 level lower than 1%
 - c. Both of the above populations**
 - d. Neither of the above populations
3. In the Phase III EVOKE-01 study evaluating sacituzumab govitecan versus docetaxel for advanced NSCLC previously treated with platinum chemotherapy and an immune checkpoint inhibitor, which of the following statements best describes the OS outcomes?
 - a. EVOKE-01 met its primary endpoint of OS improvement with sacituzumab govitecan
 - b. EVOKE-01 did not meet its primary endpoint of OS improvement, but showed numerical improvement for multiple subgroups**
 - c. OS data was immature and therefore not reported
4. In the 5-year update of the EMPOWER-Lung 1 study of cemiplimab monotherapy as first-line treatment for advanced NSCLC with PD-L1 expression $\geq 50\%$, what was the approximate 5-year OS rate for the cemiplimab arm?
 - a. 5%
 - b. 29%**
 - c. 45%
5. In the Phase III CheckMate 227 Part 1 study comparing various combinations of nivolumab, ipilimumab and chemotherapy as first-line therapy for advanced NSCLC, which of the following regimens conferred the greatest median OS benefit for patients with PD-L1 $\geq 1\%$?
 - a. Nivolumab monotherapy
 - b. Nivolumab and ipilimumab**
 - c. Chemotherapy